SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Syneos Health, Inc. – ‘8-K’ for 8/6/18 – ‘EX-5.1’

On:  Wednesday, 8/8/18, at 4:43pm ET   ·   For:  8/6/18   ·   Accession #:  1193125-18-242847   ·   File #:  1-36730

Previous ‘8-K’:  ‘8-K’ on / for 8/3/18   ·   Next:  ‘8-K’ on / for 8/20/18   ·   Latest:  ‘8-K’ on / for 10/3/23   ·   5 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 8/08/18  Syneos Health, Inc.               8-K:1,9     8/06/18    3:202K                                   Donnelley … Solutions/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     15K 
 2: EX-1.1      Underwriting Agreement                              HTML    138K 
 3: EX-5.1      Opinion re: Legality                                HTML     10K 


EX-5.1   —   Opinion re: Legality


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-5.1  

Exhibit 5.1

 

LOGO   

Wyrick Robbins Yates & Ponton LLP

 

ATTORNEYS AT LAW

 

4101 Lake Boone Trail, Suite 300, Raleigh, NC 27607

 

PO Drawer 17803, Raleigh, NC 27619

 

P: 919.781.4000 F: 919.781.4865 www.wyrick.com

August 8, 2018

Board of Directors

Syneos Health, Inc.

3201 Beechleaf Court, Suite 600

Raleigh, North Carolina 27604-1547

Ladies and Gentlemen:

We have acted as counsel to Syneos Health, Inc., a Delaware corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b) of the Securities Act of 1933, as amended (the “Act”), of a prospectus supplement, dated August 6, 2018 and filed with the Commission on August 8, 2018 (the “Prospectus Supplement”), to the prospectus, dated December 1, 2015 (the “Base Prospectus,” and together with the Prospectus Supplement, the “Prospectus”) included as part of the Registration Statement on Form S-3 (Registration No. 333-208286) (the “Registration Statement”) relating to the sale by certain stockholders of the Company of 6,000,000 shares (the “Shares”) of the Company’s Class A common stock, par value $0.01 per share (“Common Stock”). The Shares are being sold to the underwriter (the “Underwriter”) named in the Underwriting Agreement dated as of August 6, 2018 (the Underwriting Agreement) by and among the Company, the Underwriter, and the stockholders named therein.

This opinion is being furnished in accordance with the requirements of Item 16 of Form S-3 and Item 601(b)(5)(i) of Regulation S-K.

In connection with the foregoing, we have relied upon, among other things, our examination of such documents, records of the Company and certificates of its officers and public officials as we deemed necessary for purposes of the opinions expressed below. In our examination of documents for purposes of this opinion, we have assumed, and express no opinion as to, the authenticity and completeness of all documents submitted to us as originals, the conformity to originals and completeness of all documents submitted to us as copies, the legal capacity of all persons or entities executing the same, the lack of any undisclosed termination, modification, waiver or amendment to any document reviewed by us, and the due authorization, execution and delivery of all documents by the stockholders where due authorization, execution and delivery are prerequisites to the effectiveness thereof.


Board of Directors

Syneos Health, Inc.

August 8, 2018

Page 2

 

We render this opinion only with respect to, and express no opinion herein concerning the application or effect of the laws of any jurisdiction other than the existing Delaware General Corporation Law and reported judicial decisions relating thereto.

Based upon and subject to the foregoing and in reliance thereon and subject to the qualifications, assumptions and limitations stated herein, it is our opinion that the Shares have been duly authorized and are validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion with the Commission as Exhibit 5.1 to a Current Report on Form 8-K and the incorporation by reference of this opinion as an exhibit to the Registration Statement and reference to our firm under the heading “Legal Matters” in the prospectuses included therein. In giving this consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the Act or the rules and regulations promulgated thereunder by the Commission.

This opinion is intended solely for use in connection with sale of the Shares subject to the Registration Statement and is not to be relied upon for any other purpose. This opinion is rendered as of the date first written above and based solely on our understanding of facts in existence as of such date after the aforementioned examination. We assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that may hereafter be brought to our attention whether or not such occurrence would affect or modify any of the opinions expressed herein.

 

Very truly yours,
/s/ Wyrick Robbins Yates & Ponton LLP

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:8/8/18424B7
For Period End:8/6/18424B7
12/1/154,  424B7,  S-3ASR
 List all Filings 


5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/04/21  Syneos Health, Inc.               424B7                  1:390K                                   Donnelley … Solutions/FA
 5/05/21  Syneos Health, Inc.               424B7                  1:398K                                   Donnelley … Solutions/FA
 3/03/21  Syneos Health, Inc.               424B7                  1:405K                                   Donnelley … Solutions/FA
12/03/20  Syneos Health, Inc.               424B7                  1:397K                                   Donnelley … Solutions/FA
 9/16/20  Syneos Health, Inc.               424B7                  1:506K                                   Donnelley … Solutions/FA
Top
Filing Submission 0001193125-18-242847   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 16, 8:05:05.1pm ET